To include your compound in the COVID-19 Resource Center, submit it here.

Tuning metabolism in liver organoids

How Alnylam-MIT team used RNAi tech to better model drug metabolism in tox screens

An Alnylam-MIT collaboration has used RNAi technology to tune enzyme expression in hepatocyte-based organoids to better model drug metabolism during tox screens.

The collaboration with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) built on a series of papers by Sangeeta Bhatia and colleagues

Read the full 396 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers